TY - JOUR
T1 - MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis
AU - Barendregt, Anouk M
AU - Veldkamp, Saskia R
AU - Hissink Muller, Petra C E
AU - van de Geer, Annemarie
AU - Aarts, Cathelijn
AU - van Gulik, E Charlotte
AU - Schilham, Marco W
AU - Kessel, Christoph
AU - Keizer, Mischa P
AU - Hemke, Robert
AU - Nassar-Sheikh Rashid, Amara
AU - Dolman, Koert M
AU - Schonenberg-Meinema, Dieneke
AU - Ten Cate, Rebecca
AU - van den Berg, J Merlijn
AU - Maas, Mario
AU - Kuijpers, Taco W
N1 - Publisher Copyright: © 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Objective: To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14 and neutrophil elastase (NE), for their ability to predict treatment response and flare in patients with JIA. Methods: Using samples from two cohorts (I and II), we determined MRP8/14 and NE levels of 32 (I) and 81 (II) patients with new-onset, DMARD-naïve arthritis and compared patients who responded to treatment (defined as fulfilling ≥ adjusted ACRpedi50 response and/or inactive disease) with non-responders (defined as fulfilling < adjusted ACRpedi50 response and/or active disease) at 6 and 12 months. Secondly, we compared biomarker levels of 54 (I) and 34 (II) patients with clinically inactive disease who did or did not suffer from a flare of arthritis after 6 or 12 months. Receiver operating characteristic analyses were carried out to study the predictive value of MRP8/14 and NE for treatment response and flare. Results: For both cohorts, baseline MRP8/14 and NE levels for patients who did or did not respond to treatment were not different. Also, MRP8/14 and NE levels were not different in patients who did or did not flare. Receiver operating characteristic analysis of MRP8/14 and NE demonstrated areas under the curve <0.7 in both cohorts. Conclusion: In our cohorts, MRP8/14 and NE could not predict treatment response. Also, when patients had inactive disease, neither marker could predict flares.
AB - Objective: To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14 and neutrophil elastase (NE), for their ability to predict treatment response and flare in patients with JIA. Methods: Using samples from two cohorts (I and II), we determined MRP8/14 and NE levels of 32 (I) and 81 (II) patients with new-onset, DMARD-naïve arthritis and compared patients who responded to treatment (defined as fulfilling ≥ adjusted ACRpedi50 response and/or inactive disease) with non-responders (defined as fulfilling < adjusted ACRpedi50 response and/or active disease) at 6 and 12 months. Secondly, we compared biomarker levels of 54 (I) and 34 (II) patients with clinically inactive disease who did or did not suffer from a flare of arthritis after 6 or 12 months. Receiver operating characteristic analyses were carried out to study the predictive value of MRP8/14 and NE for treatment response and flare. Results: For both cohorts, baseline MRP8/14 and NE levels for patients who did or did not respond to treatment were not different. Also, MRP8/14 and NE levels were not different in patients who did or did not flare. Receiver operating characteristic analysis of MRP8/14 and NE demonstrated areas under the curve <0.7 in both cohorts. Conclusion: In our cohorts, MRP8/14 and NE could not predict treatment response. Also, when patients had inactive disease, neither marker could predict flares.
KW - MRP8/14
KW - S100A8/A9
KW - biomarkers
KW - calprotectin
KW - disease activity
KW - flare
KW - juvenile idiopathic arthritis
KW - neutrophil elastase
KW - prediction
KW - treatment response
UR - http://www.scopus.com/inward/record.url?scp=85090079154&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/rheumatology/kez590
DO - https://doi.org/10.1093/rheumatology/kez590
M3 - Article
C2 - 31904851
SN - 1462-0324
VL - 59
SP - 2392
EP - 2401
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 9
ER -